2SEVENTY BIO INC (TSVT) Stock Price, Quote, News and Overview
NASDAQ:TSVT - Nasdaq - US9013841070 - Common Stock - Currency: USD
TSVT Quote, Performance and Key Statistics
5
+0.01 (+0.2%)
The current stock price of TSVT is 5 USD. In the past month the price increased by 0.81%. In the past year, price increased by 4.17%.
TSVT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.84 | 323.71B | ||
| AMGN | AMGEN INC | 13.09 | 146.07B | ||
| GILD | GILEAD SCIENCES INC | 13.87 | 133.68B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.28 | 63.52B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.81B | ||
| ARGX | ARGENX SE - ADR | 100.1 | 35.88B | ||
| ONC | BEIGENE LTD-ADR | 6 | 26.10B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.72B | ||
| NTRA | NATERA INC | N/A | 20.94B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.20B | ||
| BIIB | BIOGEN INC | 7.95 | 18.43B |
Related stock screener links
About TSVT
Company Profile
2seventy Bio, Inc. operates as cell and gene therapy company. The company is headquartered in Cambridge, Massachusetts and currently employs 65 full-time employees. The company went IPO on 2021-10-18. The firm is focused on the commercialization and development of Abecma (idecabtagene vicleucel). Abecma is its B cell maturation antigen (BCMA)-targeted CAR T cell therapy for multiple myeloma, in collaboration with their partner Bristol Myers Squibb (BMS). ABECMA is a BCMA-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Abecma uses a lentiviral vector (LVV), to deliver a chimeric antigen receptor (CAR), with the potential to program a patient’s own T cells to recognize the plasma cell specific BCMA, protein on the cell surface.
Company Info
2SEVENTY BIO INC
60 Binney Street
Cambridge MASSACHUSETTS US
Employees: 274
Phone: 13394999300
2SEVENTY BIO INC / TSVT FAQ
What is the stock price of 2SEVENTY BIO INC today?
The current stock price of TSVT is 5 USD. The price increased by 0.2% in the last trading session.
What is the ticker symbol for 2SEVENTY BIO INC stock?
The exchange symbol of 2SEVENTY BIO INC is TSVT and it is listed on the Nasdaq exchange.
On which exchange is TSVT stock listed?
TSVT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for 2SEVENTY BIO INC stock?
8 analysts have analysed TSVT and the average price target is 5.1 USD. This implies a price increase of 2% is expected in the next year compared to the current price of 5. Check the 2SEVENTY BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is 2SEVENTY BIO INC worth?
2SEVENTY BIO INC (TSVT) has a market capitalization of 266.15M USD. This makes TSVT a Micro Cap stock.
How many employees does 2SEVENTY BIO INC have?
2SEVENTY BIO INC (TSVT) currently has 274 employees.
What are the support and resistance levels for 2SEVENTY BIO INC (TSVT) stock?
2SEVENTY BIO INC (TSVT) has a support level at 4.99 and a resistance level at 5.01. Check the full technical report for a detailed analysis of TSVT support and resistance levels.
Is 2SEVENTY BIO INC (TSVT) expected to grow?
The Revenue of 2SEVENTY BIO INC (TSVT) is expected to grow by 42.31% in the next year. Check the estimates tab for more information on the TSVT EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy 2SEVENTY BIO INC (TSVT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TSVT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TSVT, evaluating the profitability, health, valuation and growth aspects
- 2SEVENTY BIO INC (TSVT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- 2SEVENTY BIO INC (TSVT) Sales and EPS estimates to see what analysts future expectations are.
- 2SEVENTY BIO INC (TSVT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- 2SEVENTY BIO INC (TSVT) Insider and Institutional Ownership to learn about the owners and their transactions.
- 2SEVENTY BIO INC (TSVT) Stock Chart to make your own analysis
- 2SEVENTY BIO INC (TSVT) Latest news and press-releases to stay up to date.
Does 2SEVENTY BIO INC (TSVT) stock pay dividends?
TSVT does not pay a dividend.
When does 2SEVENTY BIO INC (TSVT) report earnings?
2SEVENTY BIO INC (TSVT) will report earnings on 2025-08-05, before the market open.
What is the Price/Earnings (PE) ratio of 2SEVENTY BIO INC (TSVT)?
2SEVENTY BIO INC (TSVT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.12).
What is the Short Interest ratio of 2SEVENTY BIO INC (TSVT) stock?
The outstanding short interest for 2SEVENTY BIO INC (TSVT) is 5.24% of its float. Check the ownership tab for more information on the TSVT short interest.
TSVT Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to TSVT. When comparing the yearly performance of all stocks, TSVT is one of the better performing stocks in the market, outperforming 95.69% of all stocks.
TSVT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TSVT. TSVT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
TSVT Financial Highlights
Over the last trailing twelve months TSVT reported a non-GAAP Earnings per Share(EPS) of -1.12. The EPS increased by 72.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -11.94% | ||
| ROE | -27.16% | ||
| Debt/Equity | 0 |
TSVT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 48% to TSVT. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 58.41% and a revenue growth 42.31% for TSVT